Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine

Advanced Drug Delivery Reviews

Volumn 64, Issue 13, 2012, Pages 1363-1384

  Zhang, Xue Qing ^a   Xu, Xiaoyang ^a,b   Bertrand, Nicolas ^b   Pridgen, Eric ^b,c   Swami, Archana ^a   Farokhzad, Omid C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

In vivo imaging; Molecular diagnostic; Nanomaterials; Nanoparticles; Nanotechnology; Personalized nanomedicine; Protein binding; Receptor mediated endocytosis; Targeted delivery

Indexed keywords

IN-VIVO IMAGING; MOLECULAR DIAGNOSTICS; PROTEIN BINDING; RECEPTOR-MEDIATED ENDOCYTOSIS; TARGETED DELIVERY;

BIOCHEMISTRY; BIOLOGICAL SYSTEMS; DIAGNOSIS; DRUG DELIVERY; MEDICAL NANOTECHNOLOGY; MOLECULAR BIOLOGY; NANOPARTICLES; NANOTECHNOLOGY;

NANOSTRUCTURED MATERIALS;

ALBUMIN; CD33 ANTIGEN; CYCLODEXTRIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FERUCARBOTRAN; GEMCITABINE; GEMTUZUMAB; LIPOSOME; LONIDAMINE; MACROGOL; NANOCARRIER; NANODIAMOND; NANOMATERIAL; NAVELBINE; OSTEONECTIN; PACLITAXEL; PACLITAXEL POLIGLUMEX; POLYGLUTAMIC ACID; POLYSORBATE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; QUANTUM DOT; SMALL INTERFERING RNA; SUPERPARAMAGNETIC IRON OXIDE; TRANSFERRIN; TRANSFERRIN RECEPTOR; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ACUTE GRANULOCYTIC LEUKEMIA; BIOSENSOR; BREAST CANCER; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CLINICAL TRIAL (TOPIC); COMPLEMENT ACTIVATION; COMPLEMENT ACTIVATION RELATED PSEUDOALLERGY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG RELEASE; DRUG TARGETING; DRUG TRANSPORT; DRUG TUMOR LEVEL; ENDOCYTOSIS; HEAD AND NECK CANCER; HUMAN; IMMUNOGENICITY; INTERNALIZATION; KIDNEY CARCINOMA; LEWIS CARCINOMA; LUNG NON SMALL CELL CANCER; MESOTHELIOMA; MOLECULAR DIAGNOSIS; MONOTHERAPY; NANOARRAY; NANOENCAPSULATION; NANOMEDICINE; NANOPHARMACEUTICS; NANOTOXICOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN INTERACTION; REVIEW; SURVIVAL RATE; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT;

ANIMALS; HUMANS; INDIVIDUALIZED MEDICINE; LIGANDS; NANOMEDICINE; NANOSTRUCTURES; PROTEIN BINDING;

EID: 84867650550     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.08.005     Document Type: Review

References (231)

1. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 2005, 5:161-171.
2. Jain K.K. Role of nanobiotechnology in the development of personalized medicine. Nanomedicine (Lond) 2009, 4:249-252.
3. Jain K.K. Personalized medicine. Curr. Opin. Mol. Ther. 2002, 4:548-558.
4. Vizirianakis I.S. Nanomedicine and personalized medicine toward the application of pharmacotyping in clinical practice to improve drug-delivery outcomes. Nanomedicine 2011, 7:11-17.
5. Sakamoto J.H., van de Ven A.L., Godin B., Blanco E., Serda R.E., Grattoni A., Ziemys A., Bouamrani A., Hu T., Ranganathan S.I., De Rosa E., Martinez J.O., Smid C.A., Buchanan R.M., Lee S.Y., Srinivasan S., Landry M., Meyn A., Tasciotti E., Liu X., Decuzzi P., Ferrari M. Enabling individualized therapy through nanotechnology. Pharmacol. Res. 2010, 62:57-89.
6. Hrkach J., Von Hoff D., Ali M.M., Andrianova E., Auer J., Campbell T., De Witt D., Figa M., Figueiredo M., Horhota A., Low S., McDonnell K., Peeke E., Retnarajan B., Sabnis A., Schnipper E., Song J.J., Song Y.H., Summa J., Tompsett D., Troiano G., Van Geen Hoven T., Wright J., Lorusso P., Kantoff P.W., Bander N.H., Sweeney C., Farokhzad O.C., Langer R., Zale S. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med. 2012, 4:128ra139.
7. Barenholz Y. Doxil® - The first FDA-approved nano-drug: lessons learned. J. Control. Release 2012, 160:117-134.
8. http://clinicaltrials.gov/ct2/show/NCT01455389.
9. Hu C.M., Zhang L., Aryal S., Cheung C., Fang R.H., Zhang L. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:10980-10985.
10. Fodor S.P., Read J.L., Pirrung M.C., Stryer L., Lu A.T., Solas D. Light-directed, spatially addressable parallel chemical synthesis. Science 1991, 251:767-773.
11. Demers L.M., Ginger D.S., Park S.J., Li Z., Chung S.W., Mirkin C.A. Direct patterning of modified oligonucleotides on metals and insulators by dip-pen nanolithography. Science 2002, 296:1836-1838.
12. Lee K.B., Park S.J., Mirkin C.A., Smith J.C., Mrksich M. Protein nanoarrays generated by dip-pen nanolithography. Science 2002, 295:1702-1705.
13. Lee K.B., Lim J.H., Mirkin C.A. Protein nanostructures formed via direct-write dip-pen nanolithography. J. Am. Chem. Soc. 2003, 125:5588-5589.
14. Nam J.M., Thaxton C.S., Mirkin C.A. Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins. Science 2003, 301:1884-1886.
15. Kim B.Y., Rutka J.T., Chan W.C. Nanomedicine. N. Engl. J. Med. 2012, 363:2434-2443.
16. Thaxton C.S., Elghanian R., Thomas A.D., Stoeva S.I., Lee J.S., Smith N.D., Schaeffer A.J., Klocker H., Horninger W., Bartsch G., Mirkin C.A. Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:18437-18442.
17. Morigi V., Tocchio A., Bellavite Pellegrini C., Sakamoto J.H., Arnone M., Tasciotti E. Nanotechnology in medicine: from inception to market domination. J. Drug Deliv. 2012, 2012. 10.1155/2012/389485.
18. Wagner V., Dullaart A., Bock A.K., Zweck A. The emerging nanomedicine landscape. Nat. Biotechnol. 2006, 24:1211-1217.
19. Harper S., Usenko C., Hutchison J.E., Maddux B.L.S., Tanguay R.L. In vivo biodistribution and toxicity depends on nanomaterial composition, size, surface functionalisation and route of exposure. J. Exp. Nanosci. 2008, 3:195-206.
20. Nel A.E., Mädler L., Velegol D., Xia T., Hoek E.M.V., Somasundaran P., Klaessig F., Castranova V., Thompson M. Understanding biophysicochemical interactions at the nano-bio interface. Nat. Mater. 2009, 8:543-557.
21. Lord M.S., Foss M., Besenbacher F. Influence of nanoscale surface topography on protein adsorption and cellular response. Nano Today 2010, 5:66-78.
22. Owens D.E., Peppas N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 2006, 307:93-102.
23. Bertrand N., Leroux J.C. The journey of a drug carrier in the body: an anatomo-physiological perspective. J. Control. Release 2012, 161:152-163.
24. Moghimi S.M., Hunter A.C., Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 2001, 53:283-318.
25. Kutscher H.L., Chao P., Deshmukh M., Singh Y., Hu P., Joseph L., Reimer D.C., Stein S., Laskin D.L., Sinko P.J. Threshold size for optimal passive pulmonary targeting and retention of rigid microparticles in rats. J. Control. Release 2010, 143:31-37.
26. Gref R., Luck M., Quellec P., Marchand M., Dellacherie E., Harnisch S., Blunk T., Muller R.H. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloid Surf. B. 2000, 18:301-313.
27. Peracchia M.T., Harnisch S., Pinto-Alphandary H., Gulik A., Dedieu J.C., Desmaele D., d'Angelo J., Muller R.H., Couvreur P. Visualization of in vitro protein-rejecting properties of PEGylated stealth polycyanoacrylate nanoparticles. Biomaterials 1999, 20:1269-1275.
28. Bazile D., Prud'homme C., Bassoullet M.T., Marlard M., Spenlehauer G., Veillard M. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J. Pharm. Sci. 1995, 84:493-498.
29. Peracchia M.T., Fattal E., Desmaele D., Besnard M., Noel J.P., Gomis J.M., Appel M., d'Angelo J., Couvreur P. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J. Control. Release 1999, 60:121-128.
30. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 1986, 46:6387-6392.
31. Spisak S., Tulassay Z., Molnar B., Guttman A. Protein microchips in biomedicine and biomarker discovery. Electrophoresis 2007, 28:4261-4273.
32. Johnson C.J., Zhukovsky N., Cass A.E., Nagy J.M. Proteomics nanotechnology and molecular diagnostics. Proteomics 2008, 8:715-730.
33. Vaisocherova H., Yang W., Zhang Z., Cao Z., Cheng G., Piliarik M., Homola J., Jiang S. Ultralow fouling and functionalizable surface chemistry based on a zwitterionic polymer enabling sensitive and specific protein detection in undiluted blood plasma. Anal. Chem. 2008, 80:7894-7901.
34. Dalsin J.L., Hu B.H., Lee B.P., Messersmith P.B. Mussel adhesive protein mimetic polymers for the preparation of nonfouling surfaces. J. Am. Chem. Soc. 2003, 125:4253-4258.
35. Bachmann M.F., Jennings G.T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 2010, 10:787-796.
36. Ishihara T., Takeda M., Sakamoto H., Kimoto A., Kobayashi C., Takasaki N., Yuki K., Tanaka K.-I., Takenaka M., Igarashi R., Maeda T., Yamakawa N., Okamoto Y., Otsuka M., Ishida T., Kiwada H., Mizushima Y., Mizushima T. Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles. Pharm. Res. 2009, 26:2270-2279.
37. Semple S.C., Harasym T.O., Clow K.A., Ansell S.M., Klimuk S.K., Hope M.J. Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic acid. J. Pharmacol. Exp. Ther. 2005, 312:1020-1026.
38. Dams E.T.M., Laverman P., Oyen W.J.G., Storm G., Scherphof G.L., Van der Meer J.W.M., Corstens F.H.M., Boerman O.C. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J. Pharmacol. Exp. Ther. 2000, 292:1071-1079.
39. Ishida T., Atobe K., Wang X.Y., Kiwada H. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high dose first injection. J. Control. Release 2006, 115:251-258.
40. Laverman P., Carstens M.G., Boerman O.C., Dams E.T.M., Oyen W.J.G., Van Rooijen N., Corstens F.H.M., Storm G. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J. Pharmacol. Exp. Ther. 2001, 298:607-612.
41. Ishida T., Harada M., Wang X.Y., Ichihara M., Irimura K., Kiwada H. Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. J. Control. Release 2005, 105:305-317.
42. Koide H., Asai T., Hatanaka K., Urakami T., Ishii T., Kenjo E., Nishihara M., Yokoyama M., Ishida T., Kiwada H., Oku N. Particle-size dependent triggering of accelerated blood clearance phenomenon. Int. J. Pharm. 2008, 362:197-200.
43. Szebeni J., Muggia F., Gabizon A., Barenholz Y. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv. Drug Deliv. Rev. 2011, 63:1020-1030.
44. Moghimi S.M., Hamad I., Andresen T.L., Jorgensen K., Szebeni J. Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. FASEB J. 2006, 20:2591-2593.
45. Garbuzenko O., Zalipsky S., Qazen M., Barenholz Y. Electrostatics of PEGylated micelles and liposomes containing charged and neutral lipopolymers. Langmuir 2005, 21:2560-2568.
46. S. Zalipsky, Y. Barenholz, Liposome composition for reduction of liposome-induced complement activation, PCT Patent Application (WO 2004/078121), (2004).
47. Chanan-Khan A., Szebeni J., Savay S., Liebes L., Rafique N.M., Alving C.R., Muggia F.M. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann. Oncol. 2003, 14:1430-1437.
48. Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 2005, 216:106-121.
49. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 2010, 11:785-797.
50. Salvador-Morales C., Zhang L., Langer R., Farokhzad O.C. Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups. Biomaterials 2009, 30:2231-2240.
51. Hamad I., Christy Hunter A., Rutt K.J., Liu Z., Dai H., Moein Moghimi S. Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover. Mol. Immunol. 2008, 45:3797-3803.
52. Hamad I., Al-Hanbali O., Hunter A.C., Rutt K.J., Andresen T.L., Moghimi S.M. Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering. ACS Nano 2010, 4:6629-6638.
53. Moghimi S.M., Andersen A.J., Hashemi S.H., Lettiero B., Ahmadvand D., Hunter A.C., Andresen T.L., Hamad I., Szebeni J. Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead. J. Control. Release 2010, 146:175-181.
54. Salvador-Morales C., Flahaut E., Sim E., Sloan J., Green M.L., Sim R.B. Complement activation and protein adsorption by carbon nanotubes. Mol. Immunol. 2006, 43:193-201.
55. Chonn A., Cullis P.R., Devine D.V. The role of surface-charge in the activation of the classical and alternative pathways of complement by liposomes. J. Immunol. 1991, 146:4234-4241.
56. Rensen P.C., Van Dijk M.C., Havenaa E.C., Bijsterbosch M.K., Kar Krujit J., Van Berkel T.J.C. Selective liver targeting of antivirals by recombinant chylomicrons: a new therapeutic approach to hepatitis B. Nat. Med. 1995, 1:221-225.
57. Michaelis K., Hoffman M., Dreis S., Herbert E., Alyautdin R., Michaelis M., Kreuter J., Langer K. Covalent linkage of apolipoprotein E to albumin nanoparticles strongly enhances drug transport into the brain. J. Pharmacol. Exp. Ther. 2006, 317:1246-1253.
58. Kreuter J., Hekmatara T., Dreis S., Vogel T., Gelperina S., Langer K. Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. J. Control. Release 2007, 118:54-58.
59. Desai N., Trieu V., Damascelli B., Soon-Shiong P. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl. Oncol. 2009, 2:59-64.
60. Sage H., Johnson C., Bornstein P. Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture. J. Biol. Chem. 1984, 259:3993-4007.
61. Podhajcer O.L., Benedetti L.G., Girotti M.R., Prada F., Salvatierra E., Llera A.S. The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev. 2008, 27:691-705.
62. Desai N.P., Trieu V., Hwang L.Y., Wu R., Soon-Shiong P., Gradishar W.J. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs 2008, 19:899-909.
63. Shao H., Tang H., Salavaggione O.E., Yu C., Hylander B., Tan W., Repasky E., Adjei A.A., Dy G.K. Improved response to nab-paclitaxel compared with cremophor-solubilized paclitaxel is independent of secreted protein acidic and rich in cysteine expression in non-small cell lung cancer. J. Thorac. Oncol. 2011, 6:998-1005.
64. Desai N., Trieu V., Yao Z., Louie L., Ci S., Yang A., Tao C., De T., Beals B., Dykes D., Noker P., Yao R., Labao E., Hawkins M., Soon-Shiong P. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin. Cancer Res. 2006, 12:1317-1324.
65. Desai N. Nab technology: a drug delivery platform utilising endothelial gp60 receptor-based transport and tumour-derived SPARC for targeting. Drug Delivery Report Winter 2007/2008 2008, 37-41. Food and Drug Administration.
66. Chrousos G.P. Stress and disorders of the stress system. Nat. Rev. Endocrinol. 2009, 5:374-381.
67. Fujita Y., Kakino A., Harada-Shiba M., Sato Y., Otsui K., Yoshimoto R., Sawamura T. C-reactive protein uptake by macrophage cell line via class-A scavenger receptor. Clin. Chem. 2010, 56:478-481.
68. Mihlan M., Stippa S., Józsi M. Monomeric CRP contributes to complement control in fluid phase and on cellular surfaces and increases phagocytosis by recruiting factor H. Cell Death Differ. 2009, 16:1630-1640.
69. Farokhzad O.C., Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 3:16-20.
70. Mammen M., Choi S.K., Whitesides G.M. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Ed. 1998, 37:2754-2794.
71. Rao J., Lahiri J., Isaacs L., Weis R.M., Whitesides G.M. A trivalent system from Vancomycin-d-Ala-d-Ala with higher affinity than avidin-biotin. Science 1998, 280:708-711.
72. Gao H., Shi W., Freund L.B. Mechanics of receptor-mediated endocytosis. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:9469-9474.
73. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2:751-760.
74. Shi J., Xiao Z., Kamaly N., Farokhzad O.C. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. Acc. Chem. Res. 2011, 44:1123-1134.
75. Matthay K.K., Abai A.M., Cobb S., Hong K., Papahadjopoulos D., Straubinger R.M. Role of ligand in antibody-directed endocytosis of liposomes by human T-leukemia cells. Cancer Res. 1989, 49:4879-4886.
76. Qian Z.M., Li H., Sun H., Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev. 2002, 54:561-587.
77. Friden P.M., Walus L.R., Musso G.F., Taylor M.A., Malfroy B., Starzyk R.M. Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:4771-4775.
78. Dautry-Varsat A., Ciechanover A., Lodish H.F. pH and the recycling of transferrin during receptor-mediated endocytosis. Proc. Natl. Acad. Sci. U. S. A. 1983, 80:2258-2262.
79. Davis M.E. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol. Pharm. 2009, 6:659-668.
80. Davis M.E., Zuckerman J.E., Choi C.H., Seligson D., Tolcher A., Alabi C.A., Yen Y., Heidel J.D., Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.
81. Tsutsui S., Ohno S., Murakami S., Hachitanda Y., Oda S. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res. Treat. 2002, 71:67-75.
82. Milane L., Duan Z., Amiji M. Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer. PLoS One 2011, 6:e24075.
83. Zhang X.Q., Lam R., Xu X., Chow E.K., Kim H.J., Ho D. Multimodal nanodiamond drug delivery carriers for selective targeting, imaging, and enhanced chemotherapeutic efficacy. Adv. Mater. 2011, 23:4770-4775.
84. Irvin W.J., Carey L.A. What is triple-negative breast cancer?. Eur. J. Cancer 2008, 44:2799-2805.
85. Lidke D.S., Nagy P., Heintzmann R., Arndt-Jovin D.J., Post J.N., Grecco H.E., Jares-Erijman E.A., Jovin T.M. Quantum dot ligands provide new insights into erbB/HER receptor-mediated signal transduction. Nat. Biotechnol. 2004, 22:198-203.
86. Leamon C.P., Low P.S. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:5572-5576.
87. Sega E.I., Low P.S. Tumor detection using folate receptor-targeted imaging agents. Cancer Metastasis Rev. 2008, 27:655-664.
88. Kawaguchi R., Yu J., Honda J., Hu J., Whitelegge J., Ping P., Wiita P., Bok D., Sun H. A membrane receptor for retinol binding protein mediates cellular uptake of vitamin A. Science 2007, 315:820-825.
89. Sato Y., Murase K., Kato J., Kobune M., Sato T., Kawano Y., Takimoto R., Takada K., Miyanishi K., Matsunaga T., Takayam T., Niitsu Y. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat. Biotechnol. 2008, 26:431-442.
90. Farokhzad O.C., Cheng J., Teply B.A., Sherifi I., Jon S., Kantoff P.W., Richie J.P., Langer R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:6315-6320.
91. Dhar S., Kolishetti N., Lippard S.J., Farokhzad O.C. Targeted delivery of cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:1850-1855.
92. Griffin J.D., Linch D., Sabbath K., Larcom P., Schlossman S.F. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk. Res. 1984, 8:521-534.
93. Simard P., Leroux J.C. pH-sensitive immunoliposomes specific to the CD33 cell surface antigen of leukemic cells. Int. J. Pharm. 2009, 381:86-96.
94. Torchilin V.P., Lukyanov A.N., Gao Z., Papahadjopoulos-Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:6039-6044.
95. Koning G.A., Morselt H.W.M., Gorter A., Allen T.M., Zalipsky S., Kamps J.A.A.M., Scherphof G.L. Pharmacokinetics of differently designed immunoliposome formulations in rats with or without hepatic colon cancer metastases. Pharm. Res. 2001, 18:1291-1298.
96. Allen T.M. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2002, 2:750-763.
97. Park J.W., Hong K., Kirpotin D.B., Colbern G., Shalaby R., Baselga J., Shao Y., Nielsen U.B., Marks J.D., Moore D., Papahadjopoulos D., Benz C. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. 2002, 8:1172-1181.
98. McDevitt M.R., Chattopadhyay D., Kappel B.J., Jaggi J.S., Schiffman S.R., Antczak C., Njardarson J.T., Brentjens R., Scheinberg D.A. Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. J. Nucl. Med. 2007, 48:1180-1189.
99. Simard P., Leroux J.C. In vivo evaluation of pH-sensitive polymer-based immunoliposomes targeting the CD33 antigen. Mol. Pharm. 2010, 7:1098-1107.
100. Veiseh O., Gunn J.W., Kievit F.M., Sun C., Fang C., Lee J.S.H., Zhang M. Inhibition of tumor-cell invasion with chlorotoxin-bound superparamagnetic nanoparticles. Small 2009, 5:256-264.
101. Weissleder R., Kelly K., Yi Sun E., Shtatland T., Josephson L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat. Biotechnol. 2005, 23:1418-1423.
102. Haun J.B., Devaraj N.K., Hilderbrand S.A., Lee H., Weissleder R. Bioorthogonal chemistry amplifies nanoparticle binding and enhances the sensitivity of cell detection. Nat. Nanotechnol. 2010, 5:660-665.
103. Müller M.K., Brunsweld L. A supramolecular polymer as a self-assembling polyvalent scaffold. Angew. Chem. Int. Ed. 2009, 48:2921-2924.
104. Chung H.J., Reiner T., Budin G., Min C., Liong M., Issadore D., Lee H., Weissleder R. Ubiquitous detection of Gram-positive bacteria with bioorthogonal magnetofluorescent nanoparticles. ACS Nano 2011, 5:8834-8841.
105. Kamaly N., Xiao Z., Valencia P.M., Radovic-Moreno A.F., Farokhzad O.C. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem. Soc. Rev. 2012, 41:2971-3010.
106. Burg M., Ravey E.P., Gonzales M., Amburn E., Faix P.H., Baird A., Larocca D. Selection of internalizing ligand-display phage using rolling circle amplification for phage recovery. DNA Cell Biol. 2004, 23:457-462.
107. Hild W., Pollinger K., Caporale A., Cabrele C., Keller M., Pluym N., Buschauer A., Rachel R., Tessmar J., Breunig M., Goepferich A. G protein-coupled receptors function as logic gates for nanoparticle binding and cell uptake. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:10667-10672.
108. Xiao Z., Levy-Nissenbaum E., Alexis F., Luptak A., Teply B.A., Chan J.M., Shi J., Digga E., Cheng J., Langer R., Farokhzad O.C. Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection. ACS Nano 2012, 6:696-704.
109. Yang L., Zhang X., Ye M., Jiang J., Yang R., Fu T., Chen Y., Wang K., Liu C., Tan W. Aptamer-conjugated nanomaterials and their applications. Adv. Drug Deliv. Rev. 2011, 63:1361-1370.
110. Jiang W., Kim B.Y., Rutka J.T., Chan W.C. Nanoparticle-mediated cellular response is size-dependent. Nat. Nanotechnol. 2008, 3:145-150.
111. Gu F., Zhang L., Teply B.A., Mann N., Wang A., Radovic-Moreno A.F., Langer R., Farokhzad O.C. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:2586-2591.
112. Wang J., Tian S., Petros R.A., Napier M.E., DeSimone J. The complex role of multivalency in nanoparticles targeting the transferrin receptor for cancer therapies. J. Am. Chem. Soc. 2010, 132:11306-11313.
113. Vasey P.A., Kaye S.B., Morrison R., Twelves C., Wilson P., Duncan R., Thomson A.H., Murray L.S., Hilditch T.E., Murray T., Burtles S., Fraier D., Frigerio E., Cassidy J. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin. Cancer Res. 1999, 5:83-94.
114. Miller K., Erez R., Segal E., Shabat D., Satchi-Fainaro R. Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate. Angew. Chem. Int. Ed. 2009, 48:2949-2954.
115. Ulbrich K., Subr V. Polymeric anticancer drugs with pH-controlled activation. Adv. Drug Deliv. Rev. 2004, 56:1023-1050.
116. Bareford L.M., Swaan P.W. Endocytic mechanisms for targeted drug delivery. Adv. Drug Deliv. Rev. 2007, 59:748-758.
117. Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 2009, 8:129-138.
118. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 2006, 6:688-701.
119. Minko T., Kopeckova P., Pozharov V., Kopecek J. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J. Control. Release 1998, 54:223-233.
120. Singer J.W., Shaffer S., Baker B., Bernareggi A., Stromatt S., Nienstedt D., Besman M. Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane. Anticancer Drugs 2005, 16:243-254.
121. Seymour L.W., Ulbrich K., Steyger P.S., Brereton M., Subr V., Strohalm J., Duncan R. Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br. J. Cancer 1994, 70:636-641.
122. Gianasi E., Buckley R.G., Latigo J., Wasil M., Duncan R. HPMA copolymers platinates containing dicarboxylato ligands. Preparation, characterisation and in vitro and in vivo evaluation. J. Drug Target. 2002, 10:549-556.
123. Duncan R., Vicent M.J. Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities. Adv. Drug Deliv. Rev. 2010, 62:272-282.
124. Meerum Terwogt J.M., ten Bokkel Huinink W.W., Schellens J.H., Schot M., Mandjes I.A., Zurlo M.G., Rocchetti M., Rosing H., Koopman F.J., Beijnen J.H. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs 2001, 12:315-323.
125. Schoemaker N.E., Van Kesteren C., Rosing H., Jansen S., Swart M., Lieverst J., Fraier D., Breda M., Pellizzoni C., Spinelli R., Grazia Porro M., Beijnen J.H., Schellens J.H., ten Bokkel Huinink W.W. A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin. Br. J. Cancer 2002, 87:608-614.
126. Bissett D., Cassidy J., de Bono J.S., Muirhead F., Main M., Robson L., Fraier D., Magne M.L., Pellizzoni C., Porro M.G., Spinelli R., Speed W., Twelves C. Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT). Br. J. Cancer 2004, 91:50-55.
127. Wachters F.M., Groen H.J., Maring J.G., Gietema J.A., Porro M., Dumez H., de Vries E.G., van Oosterom A.T. A phase I study with MAG-camptothecin intravenously administered weekly for 3weeks in a 4-week cycle in adult patients with solid tumours. Br. J. Cancer 2004, 90:2261-2267.
128. Duncan R., Cable H.C., Lloyd J.B., Rejmanova P., Kopecek J. Degradation of side-chains of N-(2-hydroxypropyl)methacrylamide copolymers by lysosomal thiol-proteinases. Biosci. Rep. 1982, 2:1041-1046.
129. Castino R., Demoz M., Isidoro C. Destination 'lysosome': a target organelle for tumour cell killing?. J. Mol. Recognit. 2003, 16:337-348.
130. Singer J.W., Baker B., De Vries P., Kumar A., Shaffer S., Vawter E., Bolton M., Garzone P. Poly-(l)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data. Adv. Exp. Med. Biol. 2003, 519:81-99.
131. Shaffer S.A., Baker Lee C., Kumar A., Singer J.W. Proteolysis of xyotax by lysosomal cathepsin B; metabolic profiling in tumor cells using LC-MS. Eur. J. Cancer 2002, 38:S129-S.
132. Langer C.J. CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanes. Clin. Lung Cancer 2004, 6(Suppl. 2):S85-S88.
133. Langer C.J., Socinski M.A., Ross H., O'Byrne K.J. Paclitaxel poliglumex (PPX)/carboplatin vs paclitaxel/carboplatin for the treatment of PS2 patients with chemotherapy-naive advanced non-small cell lung cancer (NSCLC): a phase III study. J. Clin. Oncol. 2005, 23:1095S-S.
134. Paz-Ares L., Ross H., O'Brien M., Riviere A., Gatzemeier U., Von Pawel J., Kaukel E., Freitag L., Digel W., Bischoff H., Garcia-Campelo R., Iannotti N., Reiterer P., Bover I., Prendiville J., Eisenfeld A., Oldham F., Bandstra B., Singer J., Bonomi P. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br. J. Cancer 2008, 98:1608-1613.
135. Kremer M., Judd J., Rifkin B., Auszmann J., Oursler M.J. Estrogen modulation of osteoclast lysosomal enzyme secretion. J. Cell. Biochem. 1995, 57:271-279.
136. Mukherjee S., Ghosh R.N., Maxfield F.R. Endocytosis. Physiol. Rev. 1997, 77:759-803.
137. Roux E., Lafleur M., Lataste É., Moreau P., Leroux J.-C. On the characterization of pH-sensitive liposome/polymer complexes. Biomacromolecules 2003, 4:240-248.
138. Bertrand N., Fleischer J.G., Wasan K.M., Leroux J.C. Pharmacokinetics and biodistribution of N-isopropylacrylamide copolymers for the design of pH-sensitive liposomes. Biomaterials 2009, 30:2598-2605.
139. Johnson R.P., Jeong Y.I., Choi E., Chung C.W., Kang D.H., Oh S.O., Suh H., Kim I. Biocompatible poly(2-hydroxyethyl methacrylate)-b-poly(l-histidine) hybrid materials for pH-sensitive intracellular anticancer drug delivery. Adv. Funct. Mater. 2012, 22:1058-1068.
140. Xu Q., Liu Y.X., Su S.S., Li W., Chen C.Y., Wu Y. Anti-tumor activity of paclitaxel through dual-targeting carrier of cyclic RGD and transferrin conjugated hyperbranched copolymer nanoparticles. Biomaterials 2012, 33:1627-1639.
141. Gao W., Langer R., Farokhzad O.C. Poly(ethylene glycol) with observable shedding. Angew. Chem. Int. Ed. 2010, 49:6567-6571.
142. Cerritelli S., Velluto D., Hubbell J.A. PEG-SS-PPS: reduction-sensitive disulfide block copolymer vesicles for intracellular drug delivery. Biomacromolecules 2007, 8:1966-1972.
143. Plank C., Oberhauser B., Mechtler K., Koch C., Wagner E. The influence of endosome-disruptive peptides on gene transfer using synthetic virus-like gene transfer systems. J. Biol. Chem. 1994, 269:12918-12924.
144. Varkouhi A.K., Scholte M., Storm G., Haisma H.J. Endosomal escape pathways for delivery of biologicals. J. Control. Release 2011, 151:220-228.
145. Palanca-Wessels M.C., Convertine A.J., Cutler-Storm R., Booth G.C., Lee F., Berguig G.Y., Stayton P.S., Press O. Anti-CD22 antibody targeting of pH-responsive micelles enhances small interfering RNA delivery and gene silencing in lymphoma cells. Mol. Ther. 2011, 19:1529-1537.
146. Yessine M.-A., Lafleur M., Meier C., Petereit H.-U., Leroux J.-C. Characterization of the membrane-destabilizing properties of different pH-sensitive methacrylic acid copolymers. Biochim. Biophys. Acta 2003, 1613:28-38.
147. Muro S., Schuchman E.H., Muzykantov V.R. Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis. Mol. Ther. 2006, 13:135-141.
148. Wu H., Hait W.N., Yang J.M. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res. 2003, 63:1515-1519.
149. Pai S.I., Lin Y.Y., Macaes B., Meneshian A., Hung C.F., Wu T.C. Prospects of RNA interference therapy for cancer. Gene Ther. 2006, 13:464-477.
150. Marshall J. Draft guidelines for nanomedicine unveiled. Nature News 2011, 10.1038/news.2011.562.
151. Golub T.R., Slonim D.K., Tamayo P., Huard C., Gaasenbeek M., Mesirov J.P., Coller H., Loh M.L., Downing J.R., Caligiuri M.A., Bloomfield C.D., Lander E.S. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286:531-537.
152. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., Boldrick J.C., Sabet H., Tran T., Yu X., Powell J.I., Yang L., Marti G.E., Moore T., Hudson J., Lu L., Lewis D.B., Tibshirani R., Sherlock G., Chan W.C., Greiner T.C., Weisenburger D.D., Armitage J.O., Warnke R., Levy R., Wilson W., Grever M.R., Byrd J.C., Botstein D., Brown P.O., Staudt L.M. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
153. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., Fluge O., Pergamenschikov A., Williams C., Zhu S.X., Lonning P.E., Borresen-Dale A.L., Brown P.O., Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
154. Bittner M., Meltzer P., Chen Y., Jiang Y., Seftor E., Hendrix M., Radmacher M., Simon R., Yakhini Z., Ben-Dor A., Sampas N., Dougherty E., Wang E., Marincola F., Gooden C., Lueders J., Glatfelter A., Pollock P., Carpten J., Gillanders E., Leja D., Dietrich K., Beaudry C., Berens M., Alberts D., Sondak V. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000, 406:536-540.
155. Azzazy H.M., Mansour M.M., Kazmierczak S.C. Nanodiagnostics: a new frontier for clinical laboratory medicine. Clin. Chem. 2006, 52:1238-1246.
156. Geho D.H., Jones C.D., Petricoin E.F., Liotta L.A. Nanoparticles: potential biomarker harvesters. Curr. Opin. Chem. Biol. 2006, 10:56-61.
157. Peng X.H., Cao Z.H., Xia J.T., Carlson G.W., Lewis M.M., Wood W.C., Yang L. Real-time detection of gene expression in cancer cells using molecular beacon imaging: new strategies for cancer research. Cancer Res. 2005, 65:1909-1917.
158. Yezhelyev M.V., Al-Hajj A., Morris C., Marcus A.I., Liu T., Lewis M., Cohen C., Zrazhevskiy P., Simons J.W., Rogatko A., Nie S., Gao X., O'Regan R.M. In situ molecular profiling of breast cancer biomarkers with multicolor quantum dots. Adv. Mater. 2007, 19:3146-3151.
159. Luchini A., Geho D.H., Bishop B., Tran D., Xia C., Dufour R.L., Jones C.D., Espina V., Patanarut A., Zhou W., Ross M.M., Tessitore A., Petricoin E.F., Liotta L.A. Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation. Nano Lett. 2008, 8:350-361.
160. Weissleder R., Stark D.D., Engelstad B.L., Bacon B.R., Compton C.C., White D.L., Jacobs P., Lewis J. Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR Am. J. Roentgenol. 1989, 152:167-173.
161. Dave S.R., Gao X. Monodisperse magnetic nanoparticles for biodetection, imaging, and drug delivery: a versatile and evolving technology. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2009, 1:583-609.
162. Emerich D.F., Thanos C.G. Targeted nanoparticle-based drug delivery and diagnosis. J. Drug Target 2007, 15:163-183.
163. Wang Y. Superparamagnetic iron oxide based MRI contrast agents: current status of clinical application. Quant. Imaging Med. Surg. 2011, 1:35-40.
164. Kim Y.K., Lee J.M., Kim C.S., Chung G.H., Kim C.Y., Kim I.H. Detection of liver metastases: gadobenate dimeglumine-enhanced three-dimensional dynamic phases and one-hour delayed phase MR imaging versus superparamagnetic iron oxide-enhanced MR imaging. Eur. Radiol. 2005, 15:220-228.
165. Schnorr J., Wagner S., Abramjuk C., Wojner I., Schink T., Kroencke T.J., Schellenberger E., Hamm B., Pilgrimm H., Taupitz M. Comparison of the iron oxide-based blood-pool contrast medium VSOP-C184 with gadopentetate dimeglumine for first-pass magnetic resonance angiography of the aorta and renal arteries in pigs. Invest. Radiol. 2004, 39:546-553.
166. Bremerich J., Bilecen D., Reimer P. MR angiography with blood pool contrast agents. Eur. Radiol. 2007, 17:3017-3024.
167. Reimer P., Bremer C., Allkemper T., Engelhardt M., Mahler M., Ebert W., Tombach B. Myocardial perfusion and MR angiography of chest with SH U 555 C: results of placebo-controlled clinical phase I study. Radiology 2004, 231:474-481.
168. Allkemper T., Bremer C., Matuszewski L., Ebert W., Reimer P. Contrast-enhanced blood-pool MR angiography with optimized iron oxides: effect of size and dose on vascular contrast enhancement in rabbits. Radiology 2002, 223:432-438.
169. Arbab A.S., Janic B., Haller J., Pawelczyk E., Liu W., Frank J.A. In vivo cellular imaging for translational medical research. Curr. Med. Imaging Rev. 2009, 5:19-38.
170. Derfus A.M., Chan W.C.W., Bhatia S.N. Intracellular delivery of quantum dots for live cell labeling and organelle tracking. Adv. Mater. 2004, 16:961-966.
171. Michalet X., Pinaud F.F., Bentolila L.A., Tsay J.M., Doose S., Li J.J., Sundaresan G., Wu A.M., Gambhir S.S., Weiss S. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 2005, 307:538-544.
172. Kramer-Marek G., Kiesewetter D.O., Capala J. Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules. J. Nucl. Med. 2009, 50:1131-1139.
173. Lee J.H., Huh Y.M., Jun Y.W., Seo J.W., Jang J.T., Song H.T., Kim S., Cho E.J., Yoon H.G., Suh J.S., Cheon J. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat. Med. 2007, 13:95-99.
174. Weissleder R., Lee A.S., Khaw B.A., Shen T., Brady T.J. Antimyosin-labeled monocrystalline iron oxide allows detection of myocardial infarct: MR antibody imaging. Radiology 1992, 182:381-385.
175. Kircher M.F., Mahmood U., King R.S., Weissleder R., Josephson L. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res. 2003, 63:8122-8125.
176. Chen J., Tung C.H., Mahmood U., Ntziachristos V., Gyurko R., Fishman M.C., Huang P.L., Weissleder R. In vivo imaging of proteolytic activity in atherosclerosis. Circulation 2002, 105:2766-2771.
177. Sosnovik D.E., Nahrendorf M., Deliolanis N., Novikov M., Aikawa E., Josephson L., Rosenzweig A., Weissleder R., Ntziachristos V. Fluorescence tomography and magnetic resonance imaging of myocardial macrophage infiltration in infarcted myocardium in vivo. Circulation 2007, 115:1384-1391.
178. Weissleder R., Tung C.H., Mahmood U., Bogdanov A. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat. Biotechnol. 1999, 17:375-378.
179. Song Y., Xu X., MacRenaris K.W., Zhang X.Q., Mirkin C.A., Meade T.J. Multimodal gadolinium-enriched DNA-gold nanoparticle conjugates for cellular imaging. Angew. Chem. Int. Edit. 2009, 48:9143-9147.
180. Koole R., van Schooneveld M.M., Hilhorst J., Castermans K., Cormode D.P., Strijkers G.J., de Mello Donega C., Vanmaekelbergh D., Griffioen A.W., Nicolay K., Fayad Z.A., Meijerink A., Mulder W.J. Paramagnetic lipid-coated silica nanoparticles with a fluorescent quantum dot core: a new contrast agent platform for multimodality imaging. Bioconjug. Chem. 2008, 19:2471-2479.
181. Lee J.H., Lee K., Moon S.H., Lee Y., Park T.G., Cheon J. All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery. Angew. Chem. Int. Edit. 2009, 48:4174-4179.
182. Wang A.Z., Bagalkot V., Vasilliou C.C., Gu F., Alexis F., Zhang L., Shaikh M., Yuet K., Cima M.J., Langer R., Kantoff P.W., Bander N.H., Jon S., Farokhzad O.C. Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem 2008, 3:1311-1315.
183. Bagalkot V., Zhang L., Levy-Nissenbaum E., Jon S., Kantoff P.W., Langer R., Farokhzad O.C. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett. 2007, 7:3065-3070.
184. Winter P.M., Neubauer A.M., Caruthers S.D., Harris T.D., Robertson J.D., Williams T.A., Schmieder A.H., Hu G., Allen J.S., Lacy E.K., Zhang H., Wickline S.A., Lanza G.M. Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arteriosclr. Thromb. Vasc. Biol. 2006, 26:2103-2109.
185. Flacke S., Fischer S., Scott M.J., Fuhrhop R.J., Allen J.S., McLean M., Winter P., Sicard G.A., Gaffney P.J., Wickline S.A., Lanza G.M. Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation 2001, 104:1280-1285.
186. Cyrus T., Abendschein D.R., Caruthers S.D., Harris T.D., Glattauer V., Werkmeister J.A., Ramshaw J.A., Wickline S.A., Lanza G.M. MR three-dimensional molecular imaging of intramural biomarkers with targeted nanoparticles. J. Cardiovasc. Magn. R. 2006, 8:535-541.
187. Marchant G.E. Small is beautiful: what can nanotechnology do for personalized medicine?. Current Pharmacogenomics and Personalized Medicine 2009, 7:231-237.
188. Karathanasis E., Suryanarayanan S., Balusu S.R., McNeeley K., Sechopoulos I., Karellas A., Annapragada A.V., Bellamkonda R.V. Imaging nanoprobe for prediction of outcome of nanoparticle chemotherapy by using mammography. Radiology 2009, 250:398-406.
189. Chan J.M., Zhang L., Tong R., Ghosh D., Gao W., Liao G., Yuet K.P., Gray D., Rhee J.W., Cheng J., Golomb G., Libby P., Langer R., Farokhzad O.C. Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:2213-2218.
190. Lee M., Choi J.S., Choi M.J., Pak Y.K., Rhee B.D., Ko K.S. DNA delivery to the mitochondria sites using mitochondrial leader peptide conjugated polyethylenimine. J. Drug Target 2007, 15:115-122.
191. Hu C.J., Aryal S., Zhang L. Nanoparticle-assisted combination therapies for effective cancer treatment. Ther. Deliv. 2010, 1:323-334.
192. Kolishetti N., Dhar S., Valencia P.M., Lin L.Q., Karnik R., Lippard S.J., Langer R., Farokhzad O.C. Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:17939-17944.
193. Sengupta S., Eavarone D., Capila I., Zhao G., Watson N., Kiziltepe T., Sasisekharan R. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 2005, 436:568-572.
194. Patil Y.B., Swaminathan S.K., Sadhukha T., Ma L., Panyam J. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 2010, 31:358-365.
195. De Jong W.H., Borm P.J. Drug delivery and nanoparticles: applications and hazards. Int. J. Nanomedicine 2008, 3:133-149.
196. Kagan V.E., Bayir H., Shvedova A.A. Nanomedicine and nanotoxicology: two sides of the same coin. Nanomedicine 2005, 1:313-316.
197. Shvedova A.A., Kagan V.E., Fadeel B. Close encounters of the small kind: adverse effects of man-made materials interfacing with the nano-cosmos of biological systems. Annu. Rev. Pharmacol. Toxicol. 2010, 50:63-88.
198. Singh N., Manshian B., Jenkins G.J., Griffiths S.M., Williams P.M., Maffeis T.G., Wright C.J., Doak S.H. Nanogenotoxicology: the DNA damaging potential of engineered nanomaterials. Biomaterials 2009, 30:3891-3914.
199. Bhabra G., Sood A., Fisher B., Cartwright L., Saunders M., Evans W.H., Surprenant A., Lopez-Castejon G., Mann S., Davis S.A., Hails L.A., Ingham E., Verkade P., Lane J., Heesom K., Newson R., Case C.P. Nanoparticles can cause DNA damage across a cellular barrier. Nat. Nanotechnol. 2009, 4:876-883.
200. Xia T., Li N., Nel A.E. Potential health impact of nanoparticles. Annu. Rev. Publ. Health 2009, 30:137-150.
201. Pan Y., Neuss S., Leifert A., Fischler M., Wen F., Simon U., Schmid G., Brandau W., Jahnen-Dechent W. Size-dependent cytotoxicity of gold nanoparticles. Small 2007, 3:1941-1949.
202. Tsoli M., Kuhn H., Brandau W., Esche H., Schmid G. Cellular uptake and toxicity of Au55 clusters. Small 2005, 1:841-844.
203. De Jong W.H., Hagens W.I., Krystek P., Burger M.C., Sips A.J., Geertsma R.E. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials 2008, 29:1912-1919.
204. Nabiev I., Mitchell S., Davies A., Williams Y., Kelleher D., Moore R., Gun'ko Y.K., Byrne S., Rakovich Y.P., Donegan J.F., Sukhanova A., Conroy J., Cottell D., Gaponik N., Rogach A., Volkov Y. Nonfunctionalized nanocrystals can exploit a cell's active transport machinery delivering them to specific nuclear and cytoplasmic compartments. Nano Lett. 2007, 7:3452-3461.
205. Hardman R. A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors. Environ. Health Persp. 2006, 114:165-172.
206. Sandhiya S., Dkhar S.A., Surendiran A. Emerging trends of nanomedicine - an overview. Fundam. Clin. Pharm. 2009, 23:263-269.
207. Poland C.A., Duffin R., Kinloch I., Maynard A., Wallace W.A., Seaton A., Stone V., Brown S., Macnee W., Donaldson K. Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nat. Nanotechnol. 2008, 3:423-428.
208. Dostert C., Petrilli V., Van Bruggen R., Steele C., Mossman B.T., Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008, 320:674-677.
209. Takagi A., Hirose A., Nishimura T., Fukumori N., Ogata A., Ohashi N., Kitajima S., Kanno J. Induction of mesothelioma in p53+/- mouse by intraperitoneal application of multi-wall carbon nanotube. J. Toxicol. Sci. 2008, 33:105-116.
210. Shvedova A.A., Kisin E., Murray A.R., Johnson V.J., Gorelik O., Arepalli S., Hubbs A.F., Mercer R.R., Keohavong P., Sussman N., Jin J., Yin J., Stone S., Chen B.T., Deye G., Maynard A., Castranova V., Baron P.A., Kagan V.E. Inhalation vs. aspiration of single-walled carbon nanotubes in C57BL/6 mice: inflammation, fibrosis, oxidative stress, and mutagenesis. Am. J. Physiol. Lung Cell Mol. Physiol. C. 2008, 295:L552-L565.
211. Sargent L.M., Shvedova A.A., Hubbs A.F., Salisbury J.L., Benkovic S.A., Kashon M.L., Lowry D.T., Murray A.R., Kisin E.R., Friend S., McKinstry K.T., Battelli L., Reynolds S.H. Induction of aneuploidy by single-walled carbon nanotubes. Environ. Mol. Mutagen. 2009, 50:708-717.
212. Sayes C.M., Wahi R., Kurian P.A., Liu Y., West J.L., Ausman K.D., Warheit D.B., Colvin V.L. Correlating nanoscale titania structure with toxicity: a cytotoxicity and inflammatory response study with human dermal fibroblasts and human lung epithelial cells. Toxicol. Sci. 2006, 92:174-185.
213. Oberdorster G., Oberdorster E., Oberdorster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ. Health Persp. 2005, 113:823-839.
214. Xiao G.G., Wang M., Li N., Loo J.A., Nel A.E. Use of proteomics to demonstrate a hierarchical oxidative stress response to diesel exhaust particle chemicals in a macrophage cell line. J. Biol. Chem. 2003, 278:50781-50790.
215. Nel A.E., Diaz-Sanchez D., Li N. The role of particulate pollutants in pulmonary inflammation and asthma: evidence for the involvement of organic chemicals and oxidative stress. Curr. Opin. Pulm. Med. 2001, 7:20-26.
216. Jones G., Brooks P.M. Injectable gold compounds: an overview. Br. J. Rheumatol. 1996, 35:1154-1158.
217. Fischer H.C., Chan W.C. Nanotoxicity: the growing need for in vivo study. Curr. Opin. Biotechnol. 2007, 18:565-571.
218. Nemmar A., Hoylaerts M.F., Hoet P.H., Vermylen J., Nemery B. Size effect of intratracheally instilled particles on pulmonary inflammation and vascular thrombosis. Toxicol. Appl. Pharm. 2003, 186:38-45.
219. Xia T., Kovochich M., Liong M., Zink J.I., Nel A.E. Cationic polystyrene nanosphere toxicity depends on cell-specific endocytic and mitochondrial injury pathways. ACS Nano 2008, 2:85-96.
220. Brewer J., Gurel O. Nanomedicine: Issues of Privacy and Informed Consent. Nanotech. L. & Bus. 2009, 6:45-57.
221. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., Martinez P., Matthews N., Stewart A., Tarpey P., Varela I., Phillimore B., Begum S., McDonald N.Q., Butler A., Jones D., Raine K., Latimer C., Santos C.R., Nohadani M., Eklund A.C., Spencer-Dene B., Clark G., Pickering L., Stamp G., Gore M., Szallasi Z., Downward J., Futreal P.A., Swanton C. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012, 366:883-892.
222. Longo D.L. Tumor heterogeneity and personalized medicine. N. Engl. J. Med. 2012, 366:956-957.
223. Bertrand N., Bouvet C., Moreau P., Leroux J.C. Transmembrane pH-gradient liposomes to treat cardiovascular drug intoxication. ACS Nano 2010, 4:7552-7558.
224. Forster V., Luciani P., Leroux J.C. Treatment of calcium channel blocker-induced cardiovascular toxicity with drug scavenging liposomes. Biomaterials 2012, 33:3578-3585.
225. Abi-Mosleh L., Infante R.E., Radhakrishnan A., Goldstein J.L., Brown M.S. Cyclodextrin overcomes deficient lysosome-to-endoplasmic reticulum transport of cholesterol in Niemann-Pick type C cells. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:19316-19321.
226. Liu B., Turley S.D., Burns D.K., Miller A.M., Repa J.J., Dietschy J.M. Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1-/- mouse. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:2377-2382.
227. Wright J.F., Wellman J., High K.A. Manufacturing and regulatory strategies for clinical AAV2-hRPE65. Curr. Gene Ther. 2010, 10:341-349.
228. Maguire A.M., Simonelli F., Pierce E.A., Pugh E.N., Mingozzi F., Bennicelli J., Banfi S., Marshall K.A., Testa F., Surace E.M., Rossi S., Lyubarsky A., Arruda V.R., Konkle B., Stone E., Sun J., Jacobs J., Dell'Osso L., Hertle R., Ma J.-X., Redmond M., Zhu X., Hauck B., Zelenaia O., Shindler J.S., Maguire M.G., Wright J.F., Volpe N.J., Wellman Mc Donnell J., Auricchio A., High K.A., Bennett J. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med. 2008, 358:2240-2248.
229. Maguire A.M., High K.A., Auricchio A., Wright J.F., Pierce E.A., Testa F., Mingozzi F., Bennicelli J.L., Ying G.-s., Rossi S., Fulton A., Marshall K.A., Banfi S., Chung D.C., Morgan J.I.W., Hauck B., Zelenaia O., Zhu X., Raffini L., Coppieters F., De Baere E., Shindler K.S., Volpe N.J., Surace E.M., Acerra C., Lyubarsky A., Redmond T.M., Stone E., Sun J., McDonnell J.W., Leroy B.P., Simonelli F., Bennett J. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 2009, 374:1597-1605.
230. Manno C.S., Arruda V.R., Pierce G.F., Glader B., Ragni M., Rasko J., Ozelo M.C., Hoots K., Blatt P., Konkle B., Dake M., Kaye R., Razavi M., Zajko A., Zehnder J., Nakai H., Chew A., Leonard D., Wright J.F., Lessard R.R., Sommer J.M., Tigges M., Sabatino D., Luk A., Jiang H., Mingozzi F., Couto L., Ertl H.C., High K.A., Kay M.A. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 2006, 12:342-347.
231. Guarneri V., Barbieri E., Conte P. Biomarkers predicting clinical benefit: fact or fiction?. J. Natl. Cancer Inst. 2011, 43:63-66.